For years, conventional wisdom has been that weight loss is a matter of willpower. Those who are overweight or obese just need to try harder to eat less and exercise more. But while diet and ...

Novo Nordisk's semaglutide, which could be the first oral alternative to injectable GLP-1 agonists in type 2 diabetes ... was found to be equivalent to the once-weekly injection of the drug ...

Ascletis Pharma’s rapid-fire expansion into obesity drug development has passed another milestone. | Ascletis Pharma’s ...

A retrospective study demonstrated that GLP-1 receptor agonist use before pregnancy corresponded with lower risks for ...

GLP-1 medications initially were used to help people with diabetes improve their insulin resistance and hunger cravings.

This article showcases a curated list of standout studies over the last week on topics such as cholesterol, GLP-1 drugs for ...

HealthDay News — Many patients with overweight or obesity discontinue glucagon-like peptide-1 (GLP-1) receptor agonist therapy within one year, with higher discontinuation rates seen for those without ...

The participants were divided into two groups, with half receiving weekly low-dose injections of semaglutide (Ozempic and Wegovy), a GLP-1 agonist, and the other half getting a placebo shot.

Glucagon-like peptide-1 (GLP-1) is a well-known medication used by physicians to treat Type 2 diabetes. GLP-1 has also become ...

Share on Pinterest GLP-1 and SGLT-2 drugs may be the best treatments for people with type 2 diabetes and COPD. Image credit: Visual Vic/Getty Images. Researchers estimate the number of people ...

GLP-1 therapies have demonstrated significant cardiometabolic benefits, particularly in high-risk patients with cardiovascular disease. Recent trials have shown the effectiveness of GLP-1 ...